Bernstein Maintains a Hold Rating on Merck & Co (MRK)

Merck & Co., Inc. (NYSE:MRK) is one of the Best and Cheap Stocks to Buy Right Now. On September 30, Courtney Breen from Bernstein reiterated a Hold rating on Merck & Co., Inc. (NYSE:MRK) without disclosing any price target.

Merck & Co., Inc. (NYSE:MRK) is set to announce its fiscal third quarter results on October 30. The company posted mixed results during its second quarter of 2025. The company topped Wall Street estimates with an EPS of $2.13, ahead of the consensus by $0.10. However, the revenue of $15.81 billion declined 1.90% falling short of the expectations by $66.69 million.

Management updated its full-year sales guidance for 2025 and is now expecting revenue between $64.3 billion and $65.3 billion, up from the prior guidance of $64.1 billion and $65.6 billion.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that develops and sells prescription medicines, vaccines, and animal health products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.